Effect of tadalafil add-on therapy in patients with persistant storage symptoms refractory to α1 -adrenoceptor antagonist monotherapy for benign prostatic hyperplasia: A randomized pilot trial comparing tadalafil and solifenacin.

Shinji UrakamiKohei OgawaSuguru OkaKiichi HagiwaraShoichi NagamotoHaruki AnjikiMichikata HayashidaAkihiro YanoKazushige SakaguchiKazuhiro KurosawaToshikazu Okaneya

Published in: Lower urinary tract symptoms (2018)

Tadalafil add-on therapy was not inferior to solifenacin add-on therapy in terms of effect and safety. Therefore, tadalafil could be an alternative add-on drug for patients with persistent lower urinary tract symptoms refractory to α1 -adrenoceptor antagonists.

Keyphrases

lower urinary tract symptoms
benign prostatic hyperplasia
emergency department
physical activity
clinical trial
bone marrow
depressive symptoms
adverse drug
cell therapy